{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T19:15:38Z","timestamp":1774984538043,"version":"3.50.1"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s10067-019-04763-3","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T20:04:16Z","timestamp":1576008256000},"page":"327-337","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Treating juvenile idiopathic arthritis (JIA)-related uveitis beyond TNF-\u03b1 inhibition: a narrative review"],"prefix":"10.1007","volume":"39","author":[{"given":"Carla","family":"Gaggiano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donato","family":"Rigante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Marco","family":"Tosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Grosso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Fabiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7352-1275","authenticated-orcid":false,"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,10]]},"reference":[{"key":"4763_CR1","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/art.22381","volume":"56","author":"RK Saurenmann","year":"2007","unstructured":"Saurenmann RK, Levin AV, Feldman BM, Rose JB, Laxer RM, Schneider R, Silverman ED (2007) Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term follow-up study. Arthritis Rheum 56:647\u2013657","journal-title":"Arthritis Rheum"},{"key":"4763_CR2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3109\/09273948.2013.791701","volume":"21","author":"A Heiligenhaus","year":"2013","unstructured":"Heiligenhaus A, Heinz C, Edelsten C, Kotaniemi K, Minden K (2013) Review for disease of the year: epidemiology of juvenile idiopathic arthritis and its associated uveitis: the probable risk factors. Ocul Immunol Inflamm 21:180\u2013191","journal-title":"Ocul Immunol Inflamm"},{"key":"4763_CR3","first-page":"1900","volume":"30","author":"A Martini","year":"2003","unstructured":"Martini A (2003) Are the number of joints involved or the presence of psoriasis still useful tools to identify homogeneous disease entities in juvenile idiopathic arthritis? J Rheumatol 30:1900\u20131903","journal-title":"J Rheumatol"},{"key":"4763_CR4","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.berh.2018.01.002","volume":"31","author":"ES Sen","year":"2017","unstructured":"Sen ES, Ramanan AV (2017) Juvenile idiopathic arthritis-associated uveitis. Best Pract Res Clin Rheumatol 31:517\u2013534","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"4763_CR5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12969-016-0088-2","volume":"14","author":"SL Clarke","year":"2016","unstructured":"Clarke SL, Sen ES, Ramanan AV (2016) Juvenile idiopathic arthritis-associated uveitis. Pediatr Rheumatol Online J 14:27","journal-title":"Pediatr Rheumatol Online J"},{"key":"4763_CR6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3109\/09273940903311999","volume":"18","author":"MP Paroli","year":"2010","unstructured":"Paroli MP, Spinucci G, Fabiani C, Pivetti-Pezzi P (2010) Retinal complications of juvenile idiopathic arthritis-related uveitis: a microperimetry and optical coherence tomography study. Ocul Immunol Inflamm 18:54\u201359","journal-title":"Ocul Immunol Inflamm"},{"key":"4763_CR7","first-page":"803989","volume":"2013","author":"MP Paroli","year":"2013","unstructured":"Paroli MP, Fabiani C, Spinucci G, Abicca I, Sapia A, Spadea L (2013) Severe macular edema in patients with juvenile idiopathic arthritis-related uveitis. Case Rep Ophthalmol Med 2013:803989","journal-title":"Case Rep Ophthalmol Med"},{"key":"4763_CR8","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ophtha.2012.07.052","volume":"120","author":"AC Gregory","year":"2013","unstructured":"Gregory AC, Kempen JH, Daniel E, Ka\u00e7maz RO, Foster CS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study Research Group (2013) Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the systemic immunosuppressive therapy for eye diseases study. Ophthalmology 120:186\u2013192","journal-title":"Ophthalmology"},{"key":"4763_CR9","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00296-015-3231-3","volume":"35","author":"R Bou","year":"2015","unstructured":"Bou R, Ad\u00e1n A, Borr\u00e1s F, Bravo B, Calvo I, De Inocencio J, D\u00edaz J, Escudero J, Fonollosa A, de Vicu\u00f1a CG, Hern\u00e1ndez V, Merino R, Peralta J, R\u00faa MJ, Tejada P, Ant\u00f3n J (2015) Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus. Rheumatol Int 35:777\u2013785","journal-title":"Rheumatol Int"},{"key":"4763_CR10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/092739490500282","volume":"12","author":"VL Perez","year":"2004","unstructured":"Perez VL, Papaliodis GN, Chu D, Anzaar F, Christen W, Foster CS (2004) Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies. Ocul Immunol Inflamm 12:193\u2013201","journal-title":"Ocul Immunol Inflamm"},{"key":"4763_CR11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clim.2011.01.014","volume":"139","author":"AM El-Asrar","year":"2011","unstructured":"El-Asrar AM, Struyf S, Kangave D, Al-Obeidan SS, Opdenakker G, Geboes K, Van Damme J (2011) Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Clin Immunol 139:177\u2013184","journal-title":"Clin Immunol"},{"key":"4763_CR12","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/rheumatology\/ken489","volume":"48","author":"T Yoshimura","year":"2009","unstructured":"Yoshimura T, Sonoda KH, Ohguro N, Ohsugi Y, Ishibashi T, Cua DJ, Kobayashi T, Yoshida H, Yoshimura A (2009) Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology 48:347\u2013354","journal-title":"Rheumatology"},{"key":"4763_CR13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ajo.2011.01.031","volume":"152","author":"JJ Kuiper","year":"2011","unstructured":"Kuiper JJ, Mutis T, de Jager W, de Groot-Mijnes JD, Rothova A (2011) Intraocular interleukin-17 and proinflammatory cytokines in HLA-A29-associated birdshot chorioretinopathy. Am J Ophthalmol 152:177\u2013182.e1","journal-title":"Am J Ophthalmol"},{"key":"4763_CR14","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2174\/1566524015666150731100012","volume":"15","author":"W Chen","year":"2015","unstructured":"Chen W, Zhao B, Jiang R, Zhang R, Wang Y, Wu H, Gordon L, Chen L (2015) Cytokine expression profile in aqueous humor and sera of patients with acute anterior uveitis. Curr Mol Med 15:543\u2013549","journal-title":"Curr Mol Med"},{"key":"4763_CR15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10753-015-0229-7","volume":"39","author":"L Zhang","year":"2016","unstructured":"Zhang L, Wan F, Song J, Tang K, Zheng F, Guo J, Guo D, Bi H (2016) Imbalance between Th17 cells and regulatory T cells during monophasic experimental autoimmune uveitis. Inflammation 39:113\u2013122","journal-title":"Inflammation"},{"key":"4763_CR16","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s10067-017-3672-z","volume":"36","author":"G Lopalco","year":"2017","unstructured":"Lopalco G, Fabiani C, Sota J, Lucherini OM, Tosi GM, Frediani B, Iannone F, Galeazzi M, Franceschini R, Rigante D, Cantarini L (2017) IL-6 blockade in the management of non-infectious uveitis. Clin Rheumatol 36:1459\u20131469","journal-title":"Clin Rheumatol"},{"key":"4763_CR17","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.exer.2010.04.009","volume":"91","author":"S Hohki","year":"2010","unstructured":"Hohki S, Ohguro N, Haruta H, Nakai K, Terabe F, Serada S, Fujimoto M, Nomura S, Kawahata H, Kishimoto T, Naka T (2010) Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses. Exp Eye Res 91:162\u2013170","journal-title":"Exp Eye Res"},{"key":"4763_CR18","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3899\/jrheum.160908","volume":"44","author":"E Quesada-Masachs","year":"2017","unstructured":"Quesada-Masachs E, Caballero CM (2017) Subcutaneous tocilizumab may be less effective than intravenous tocilizumab in the treatment of juvenile idiopathic arthritis-associated uveitis. J Rheumatol 44:260\u2013261","journal-title":"J Rheumatol"},{"key":"4763_CR19","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/art.39940","volume":"69","author":"V Calvo-R\u00edo","year":"2017","unstructured":"Calvo-R\u00edo V, Santos-G\u00f3mez M, Calvo I, Gonz\u00e1lez-Fern\u00e1ndez MI, L\u00f3pez-Montesinos B, Mesquida M, Ad\u00e1n A, Hern\u00e1ndez MV, Ma\u00edz O, Atanes A, Bravo B, Modesto C, D\u00edaz-Cordov\u00e9s G, Palmou-Fontana N, Loricera J, Gonz\u00e1lez-Vela MC, Demetrio-Pablo R, Hern\u00e1ndez JL, Gonz\u00e1lez-Gay MA, Blanco R (2017) Anti-Interleukin-6 receptor tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-tumor necrosis factor therapy: a multicenter study of twenty-five patients. Arthritis Rheumatol 69:668\u2013675","journal-title":"Arthritis Rheumatol"},{"key":"4763_CR20","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1080\/09273948.2017.1305420","volume":"26","author":"DS Curragh","year":"2018","unstructured":"Curragh DS, O'Neill M, McAvoy CE, Rooney M, McLoone E (2018) Pediatric uveitis in a well-defined population: improved outcomes with immunosuppressive therapy. Ocul Immunol Inflamm 26:978\u2013985","journal-title":"Ocul Immunol Inflamm"},{"key":"4763_CR21","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3899\/jrheum.120010","volume":"39","author":"C Tappeiner","year":"2012","unstructured":"Tappeiner C, Heinz C, Ganser G, Heiligenhaus A (2012) Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol 39:1294\u20131295","journal-title":"J Rheumatol"},{"key":"4763_CR22","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.3899\/jrheum.160231","volume":"43","author":"C Tappeiner","year":"2016","unstructured":"Tappeiner C, Mesquida M, Ad\u00e1n A, Anton J, Ramanan AV, Carreno E, Mackensen F, Kotaniemi K, de Boer JH, Bou R, de Vicu\u00f1a CG, Heiligenhaus A (2016) Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol 43:2183\u20132188","journal-title":"J Rheumatol"},{"key":"4763_CR23","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1016\/j.ophtha.2014.06.050","volume":"121","author":"M Mesquida","year":"2014","unstructured":"Mesquida M, Molins B, Lloren\u00e7 V, Sainz de la Maza M, Ad\u00e1n A (2014) Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema. Ophthalmology 121:2380\u20132386","journal-title":"Ophthalmology"},{"key":"4763_CR24","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/IAE.0000000000001690","volume":"38","author":"M Mesquida","year":"2018","unstructured":"Mesquida M, Molins B, Lloren\u00e7 V, Hern\u00e1ndez MV, Espinosa G, Sainz de la Maza M, Ad\u00e1n A (2018) Twenty-four month follow-up of tocilizumab therapy for refractory uveitis-related macular edema. Retina 38:1361\u20131370","journal-title":"Retina"},{"key":"4763_CR25","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1007\/s00417-013-2436-y","volume":"251","author":"A Ad\u00e1n","year":"2013","unstructured":"Ad\u00e1n A, Mesquida M, Lloren\u00e7 V, Espinosa G, Molins B, Hern\u00e1ndez MV, Pelegr\u00edn L (2013) Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol 251:2627\u20132632","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4763_CR26","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3109\/09273948.2015.1099680","volume":"25","author":"CME Deuter","year":"2017","unstructured":"Deuter CME, Zierhut M, Igney-Oertel A, Xenitidis T, Feidt A, Sobolewska B, Stuebiger N, Doycheva D (2017) Tocilizumab in Uveitic macular edema refractory to previous immunomodulatory treatment. Ocul Immunol Inflamm 25:215\u2013220","journal-title":"Ocul Immunol Inflamm"},{"key":"4763_CR27","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00417-013-2466-5","volume":"252","author":"A Ad\u00e1n","year":"2014","unstructured":"Ad\u00e1n A, Mesquida M, Lloren\u00e7 V, Modesto C (2014) Tocilizumab for retinal vasoproliferative tumor secondary to juvenile idiopathic arthritis-associated uveitis: a case report. Graefes Arch Clin Exp Ophthalmol 252:163\u2013164","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4763_CR28","doi-asserted-by":"crossref","first-page":"e400","DOI":"10.1111\/aos.13015","volume":"94","author":"S Silpa-Archa","year":"2016","unstructured":"Silpa-Archa S, Oray M, Preble JM, Foster CS (2016) Outcome of tocilizumab treatment in refractory ocular inflammatory diseases. Acta Ophthalmol 94:e400\u2013e406","journal-title":"Acta Ophthalmol"},{"key":"4763_CR29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3109\/09273948.2013.866254","volume":"22","author":"AC Tsang","year":"2014","unstructured":"Tsang AC, Roth J, Gottlieb C (2014) Tocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patient. Ocul Immunol Inflamm 22:155\u2013157","journal-title":"Ocul Immunol Inflamm"},{"key":"4763_CR30","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00417-016-3497-5","volume":"255","author":"M Breitbach","year":"2017","unstructured":"Breitbach M, Tappeiner C, B\u00f6hm MR, Zurek-Imhoff B, Heinz C, Thanos S, Ganser G, Heiligenhaus A (2017) Discontinuation of long-term adalimumab treatment in patients with juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol 255:171\u2013177","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"4763_CR31","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1136\/bjophthalmol-2018-312313","volume":"103","author":"Fernanda Maria Silveira Souto","year":"2018","unstructured":"Souto FMS, Giampietro BV, Takiuti JT, Campos LMA, Hirata CE, Yamamoto JH (2018) Clinical features of paediatric uveitis at a tertiary referral Centre in S\u00e3o Paulo, SP, Brazil. Br J Ophthalmol. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-312313","journal-title":"British Journal of Ophthalmology"},{"key":"4763_CR32","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ajo.2017.10.018","volume":"185","author":"SS Salek","year":"2018","unstructured":"Salek SS, Pradeep A, Guly C, Ramanan AV, Rosenbaum JT (2018) Uveitis and juvenile psoriatic arthritis or psoriasis. Am J Ophthalmol 185:68\u201374","journal-title":"Am J Ophthalmol"},{"key":"4763_CR33","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","volume":"372","author":"N Ruperto","year":"2008","unstructured":"Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-P\u00e9rez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-Magalh\u00e3es C, Sztajnbok F, Goldenstein-Schainberg C, Scheinberg M, Calvo Penades I, Fischbach M, Orozco J, Hashkes PJ, Hom C, Jung L, Lepore L, Oliveira S, Wallace CA, Sigal LH, Block AJ, Covucci A, Martini A, Giannini EH, for the Paediatric Rheumatology International Trials Organization (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG) (2008) Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 372:383\u2013391","journal-title":"Lancet"},{"key":"4763_CR34","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.preteyeres.2011.11.004","volume":"31","author":"F Willermain","year":"2012","unstructured":"Willermain F, Rosenbaum JT, Bodaghi B, Rosenzweig HL, Childers S, Behrend T, Wildner G, Dick AD (2012) Interplay between innate and adaptive immunity in the development of non-infectious uveitis. Prog Retin Eye Res 31:182\u2013194","journal-title":"Prog Retin Eye Res"},{"key":"4763_CR35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12026-008-8031-3","volume":"42","author":"R Caspi","year":"2008","unstructured":"Caspi R (2008) Autoimmunity in the immune privileged eye: pathogenic and regulatory T cells. Immunol Res 42:41\u201350","journal-title":"Immunol Res"},{"key":"4763_CR36","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.autrev.2011.02.001","volume":"10","author":"YT Lin","year":"2011","unstructured":"Lin YT, Wang CT, Gershwin ME, Chiang BL (2011) The pathogenesis of oligoarticular\/ polyarticular vs systemic juvenile idiopathic arthritis. Autoimmun Rev 10:482\u2013489","journal-title":"Autoimmun Rev"},{"key":"4763_CR37","first-page":"2016","volume":"42","author":"H Shao","year":"2001","unstructured":"Shao H, Woon MD, Nakamura S, Sohn JH, Morton PA, Bora NS, Kaplan HJ (2001) Requirement of B7-mediated costimulation in the induction of experimental autoimmune anterior uveitis. Invest Ophthalmol Vis Sci 42:2016\u20132021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4763_CR38","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.4049\/jimmunol.165.9.5041","volume":"165","author":"PB Silver","year":"2000","unstructured":"Silver PB, Hathcock KS, Chan CC, Wiggert B, Caspi RR (2000) Blockade of costimulation through B7\/CD28 inhibits experimental autoimmune uveoretinitis, but does not induce long-term tolerance. J Immunol 165:5041\u20135047","journal-title":"J Immunol"},{"key":"4763_CR39","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/art.27431","volume":"62","author":"N Ruperto","year":"2010","unstructured":"Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-P\u00e9rez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-Magalh\u00e3es C, Chavez-Corrales J, Huemer C, Kivitz A, Blanco FJ, Foeldvari I, Hofer M, Horneff G, Huppertz HI, Job-Deslandre C, Loy A, Minden K, Punaro M, Nunez AF, Sigal LH, Block AJ, Nys M, Martini A, Giannini EH, Paediatric Rheumatology International Trials Organization and the Pediatric Rheumatology Collaborative Study Group (2010) Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 62:1792\u20131802","journal-title":"Arthritis Rheum"},{"key":"4763_CR40","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.3899\/jrheum.151389","volume":"43","author":"C Birolo","year":"2016","unstructured":"Birolo C, Zannin ME, Arsenyeva S, Cimaz R, Miserocchi E, Dubko M, Deslandre CJ, Falcini F, Alessio M, La Torre F, Denisova E, Martini G, Nikishina I, Zulian F (2016) Comparable efficacy of Abatacept used as first-line or second-line biological agent for severe juvenile idiopathic arthritis-related uveitis. J Rheumatol 43:2068\u20132073","journal-title":"J Rheumatol"},{"key":"4763_CR41","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/acr.20115","volume":"62","author":"F Zulian","year":"2010","unstructured":"Zulian F, Balzarin M, Falcini F, Martini G, Alessio M, Cimaz R, Cimino L, Zannin ME (2010) Abatacept for severe anti-tumor necrosis factor \u03b1 refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken) 62:821\u2013825","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4763_CR42","first-page":"1897","volume":"35","author":"S Angeles-Han","year":"2008","unstructured":"Angeles-Han S, Flynn T, Lehman T (2008) Abatacept for refractory juvenile idiopathic arthritis-associated uveitis- a case report. J Rheumatol 35:1897\u20131898","journal-title":"J Rheumatol"},{"key":"4763_CR43","doi-asserted-by":"crossref","unstructured":"Alpigiani MG, Salvati P, Vannati M, Callegari S, Trovato F, Rossi R, Gamba S, Lorini R (2010) Abatacept for severe anti TNF-alpha refractory JIA-associated uveitis: a case report. 17th Pediatric Rheumatology European Society Congress. September 9-12 Val\u00e8ncia, Spain","DOI":"10.1186\/1546-0096-9-S1-P189"},{"key":"4763_CR44","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/acr.20359","volume":"63","author":"M Elhai","year":"2011","unstructured":"Elhai M, Deslandre CJ, Kahan A (2011) Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on the article by Zulian et al. Arthritis Care Res (Hoboken) 63:307\u2013308 author reply 308","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4763_CR45","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00417-010-1523-6","volume":"249","author":"N Kenawy","year":"2011","unstructured":"Kenawy N, Cleary G, Mewar D, Beare N, Chandna A, Pearce I (2011) Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol 249:297\u2013300","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4763_CR46","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3899\/jrheum.140410","volume":"42","author":"C Tappeiner","year":"2015","unstructured":"Tappeiner C, Miserocchi E, Bodaghi B, Kotaniemi K, Mackensen F, Gerloni V, Quartier P, Lutz T, Heiligenhaus A (2015) Abatacept in the treatment of severe, longstanding, and refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol 42:706\u2013711","journal-title":"J Rheumatol"},{"key":"4763_CR47","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1111\/trf.14841","volume":"58","author":"J MacIsaac","year":"2018","unstructured":"MacIsaac J, Siddiqui R, Jamula E, Li N, Baker S, Webert KE, Evanovitch D, Heddle NM, Arnold DM (2018) Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin. Transfusion 58:2729\u20132735","journal-title":"Transfusion"},{"key":"4763_CR48","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1002\/art.24601","volume":"60","author":"MG Barnes","year":"2009","unstructured":"Barnes MG, Grom AA, Thompson SD, Griffin TA, Pavlidis P, Itert L, Fall N, Sowders DP, Hinze CH, Aronow BJ, Luyrink LK, Srivastava S, Ilowite NT, Gottlieb BS, Olson JC, Sherry DD, Glass DN, Colbert RA (2009) Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. Arthritis Rheum 60:2102\u20132112","journal-title":"Arthritis Rheum"},{"key":"4763_CR49","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.coph.2004.03.006","volume":"4","author":"H Kazkaz","year":"2004","unstructured":"Kazkaz H, Isenberg D (2004) Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. Curr Opin Pharmacol 4:398\u2013402","journal-title":"Curr Opin Pharmacol"},{"key":"4763_CR50","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000336188","volume":"51","author":"E Miserocchi","year":"2012","unstructured":"Miserocchi E, Modorati G (2012) Rituximab for noninfectious uveitis. Dev Ophthalmol 51:98\u2013109","journal-title":"Dev Ophthalmol"},{"key":"4763_CR51","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.clim.2006.12.006","volume":"123","author":"PP Sfikakis","year":"2007","unstructured":"Sfikakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN, Theofilopoulos AN (2007) Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol 123:66\u201373","journal-title":"Clin Immunol"},{"key":"4763_CR52","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1007\/s00415-013-6987-y","volume":"260","author":"V Catzola","year":"2013","unstructured":"Catzola V, Battaglia A, Buzzonetti A, Fossati M, Scuderi F, Fattorossi A, Evoli A (2013) Changes in regulatory T cells after rituximab in two patients with refractory myasthenia gravis. J Neurol 260:2163\u20132165","journal-title":"J Neurol"},{"key":"4763_CR53","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/cyto.990140212","volume":"14","author":"LE Hultin","year":"1993","unstructured":"Hultin LE, Hausner MA, Hultin PM, Giorgi JV (1993) CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry 14:196\u2013204","journal-title":"Cytometry"},{"key":"4763_CR54","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/rheumatology\/ker107","volume":"50","author":"A Heiligenhaus","year":"2011","unstructured":"Heiligenhaus A, Miserocchi E, Heinz C, Gerloni V, Kotaniemi K (2011) Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford) 50:1390\u20131394","journal-title":"Rheumatology (Oxford)"},{"key":"4763_CR55","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ophtha.2010.07.031","volume":"118","author":"E Miserocchi","year":"2011","unstructured":"Miserocchi E, Pontikaki I, Modorati G, Bandello F, Meroni PL, Gerloni V (2011) Rituximab for uveitis. Ophthalmology 118:223\u2013224","journal-title":"Ophthalmology"},{"key":"4763_CR56","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1136\/bjophthalmol-2015-306790","volume":"100","author":"E Miserocchi","year":"2016","unstructured":"Miserocchi E, Modorati G, Berchicci L, Pontikaki I, Meroni P, Gerloni V (2016) Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. Br J Ophthalmol 100:782\u2013786","journal-title":"Br J Ophthalmol"},{"key":"4763_CR57","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3899\/jrheum.130206","volume":"41","author":"L Pelegrin","year":"2014","unstructured":"Pelegrin L, Jakob E, Schmidt-Bacher A, Schwenger V, Becker M, Max R, Lorenz HM, Mackensen F (2014) Experiences with rituximab for the treatment of autoimmune diseases with ocular involvement. J Rheumatol 41:84\u201390","journal-title":"J Rheumatol"},{"key":"4763_CR58","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, REFLEX Trial Group (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54:2793\u20132806","journal-title":"Arthritis Rheum"},{"key":"4763_CR59","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","volume":"31","author":"E Kimby","year":"2005","unstructured":"Kimby E (2005) Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 31:456\u2013473","journal-title":"Cancer Treat Rev"},{"key":"4763_CR60","doi-asserted-by":"crossref","first-page":"452","DOI":"10.4049\/jimmunol.158.1.452","volume":"158","author":"Y Guex-Crosier","year":"1997","unstructured":"Guex-Crosier Y, Raber J, Chan CC, Kriete MS, Benichou J, Pilson RS, Kerwin JA, Waldmann TA, Hakimi J, Roberge FG (1997) Humanized antibodies against the \u03b1-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. J Immunol 158:452\u2013458","journal-title":"J Immunol"},{"key":"4763_CR61","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1136\/bjo.2007.124081","volume":"91","author":"M Gallagher","year":"2007","unstructured":"Gallagher M, Quinones K, Cervantes-Casta\u00f1eda RA, Yilmaz T, Foster CS (2007) Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol 91:1341\u20131344","journal-title":"Br J Ophthalmol"},{"key":"4763_CR62","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.ajo.2009.06.003","volume":"148","author":"HN Sen","year":"2009","unstructured":"Sen HN, Levy-Clarke G, Faia LJ, Li Z, Yeh S, Barron KS, Ryan JG, Hammel K, Nussenblatt RB (2009) High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis. Am J Ophthalmol 148:696\u2013703.e1","journal-title":"Am J Ophthalmol"},{"key":"4763_CR63","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1073\/pnas.96.13.7462","volume":"96","author":"RB Nussenblatt","year":"1999","unstructured":"Nussenblatt RB, Fortin E, Schiffman R, Rizzo L, Smith J, Van Veldhuisen P, Sran P, Yaffe A, Goldman CK, Waldmann TA, Whitcup SM (1999) Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-tac mAb: a phase I\/II clinical trial. Proc Natl Acad Sci U S A 96:7462\u20137466","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4763_CR64","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ophtha.2004.12.034","volume":"112","author":"RB Nussenblatt","year":"2005","unstructured":"Nussenblatt RB, Peterson JS, Foster CS, Rao NA, See RF, Letko E, Buggage RR (2005) Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 112:764\u2013770","journal-title":"Ophthalmology"},{"key":"4763_CR65","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1007\/s10067-016-3527-z","volume":"36","author":"C Fabiani","year":"2017","unstructured":"Fabiani C, Sota J, Tosi GM, Franceschini R, Frediani B, Galeazzi M, Rigante D, Cantarini L (2017) The emerging role of interleukin (IL)-1 in the pathogenesis and treatment of inflammatory and degenerative eye diseases. Clin Rheumatol 36:2307\u20132318","journal-title":"Clin Rheumatol"},{"key":"4763_CR66","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.3899\/jrheum.160064","volume":"43","author":"A Brambilla","year":"2016","unstructured":"Brambilla A, Caputo R, Cimaz R, Simonini G (2016) Canakinumab for childhood sight-threatening refractory uveitis: a case series. J Rheumatol 43:1445\u20131447","journal-title":"J Rheumatol"},{"key":"4763_CR67","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4103\/0301-4738.194339","volume":"64","author":"MC Guedes","year":"2016","unstructured":"Guedes MC, Borrego LM, Proen\u00e7a RD (2016) Roles of interleukin-17 in uveitis. Indian J Ophthalmol 64:628\u2013634","journal-title":"Indian J Ophthalmol"},{"key":"4763_CR68","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/j.ophtha.2018.05.014","volume":"125","author":"KL Pepple","year":"2018","unstructured":"Pepple KL, Lin P (2018) Targeting Interleukin-23 in the treatment of noninfectious uveitis. Ophthalmology 125:1977\u20131983","journal-title":"Ophthalmology"},{"key":"4763_CR69","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jmii.2014.07.002","volume":"49","author":"SA Wu","year":"2016","unstructured":"Wu SA, Yeh KW, Lee WI, Yao TC, Huang JL (2016) Persistent improper upregulation of Th17 and TReg cells in patients with juvenile idiopathic arthritis. J Microbiol Immunol Infect 49:402\u2013408","journal-title":"J Microbiol Immunol Infect"},{"key":"4763_CR70","first-page":"1107","volume":"77","author":"T Constantin","year":"2018","unstructured":"Constantin T, Foeldvari I, Anton J, de Boer J, Czitrom-Guillaume S, Edelsten C, Gepstein R, Heiligenhaus A, Pilkington CA, Simonini G, Uziel Y, Vastert SJ, Wulffraat NM, Haasnoot AM, Walscheid K, P\u00e1link\u00e1s A, Pattani R, Gy\u00f6rgyi Z, Kozma R, Boom V, Ponyi A, Ravelli A, Ramanan AV (2018) Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. Ann Rheum Dis 77:1107\u20131117","journal-title":"Ann Rheum Dis"},{"key":"4763_CR71","first-page":"819","volume":"77","author":"A Ravelli","year":"2018","unstructured":"Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, Akikusa JD, Al-Mayouf SM, Ant\u00f3n J, Avcin T, Berard RA, Beresford MW, Burgos-Vargas R, Cimaz R, De Benedetti F, Demirkaya E, Foell D, Itoh Y, Lahdenne P, Morgan EM, Quartier P, Ruperto N, Russo R, Saad-Magalh\u00e3es C, Sawhney S, Scott C, Shenoi S, Swart JF, Uziel Y, Vastert SJ, Smolen JS (2018) Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis 77:819\u2013828","journal-title":"Ann Rheum Dis"},{"key":"4763_CR72","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.ajo.2007.01.033","volume":"143","author":"JE Thorne","year":"2007","unstructured":"Thorne JE, Woreta F, Kedhar SR, Dunn JP, Jabs DA (2007) Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss. Am J Ophthalmol 143:840\u2013846","journal-title":"Am J Ophthalmol"},{"key":"4763_CR73","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","volume":"121","author":"G Levy-Clarke","year":"2014","unstructured":"Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN (2014) Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 121:785\u2013796","journal-title":"Ophthalmology"},{"key":"4763_CR74","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/acr.22214","volume":"66","author":"G Simonini","year":"2014","unstructured":"Simonini G, Druce K, Cimaz R, Macfarlane GJ, Jones GT (2014) Current evidence of anti-tumor necrosis factor \u03b1 treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs. Arthritis Care Res 66:1073\u20131084","journal-title":"Arthritis Care Res"},{"key":"4763_CR75","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","volume":"376","author":"AV Ramanan","year":"2017","unstructured":"Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot-Lacassagne S, Hardwick B, Hickey H, Hughes D, Woo P, Benton D, Edelsten C, Beresford MW, SYCAMORE Study Group (2017) Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med 376:1637\u20131646","journal-title":"N Engl J Med"},{"key":"4763_CR76","first-page":"1043","volume":"35","author":"ST Leinonen","year":"2017","unstructured":"Leinonen ST, Aalto K, Kotaniemi KM, Kivel\u00e4 TT (2017) Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis. Clin Exp Rheumatol 35:1043\u20131046","journal-title":"Clin Exp Rheumatol"},{"key":"4763_CR77","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3109\/03009742.2015.1022213","volume":"44","author":"A Skrabl-Baumgartner","year":"2015","unstructured":"Skrabl-Baumgartner A, Erwa W, Muntean W, Jahnel J (2015) Anti-adalimumab antibodies in juvenile idiopathic arthritis: frequent association with loss of response. Scand J Rheumatol 44:359\u2013362","journal-title":"Scand J Rheumatol"},{"key":"4763_CR78","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s10067-017-3890-4","volume":"37","author":"CK Correll","year":"2018","unstructured":"Correll CK, Bullock DR, Cafferty RM, Vehe RK (2018) Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis. Clin Rheumatol 37:549\u2013553","journal-title":"Clin Rheumatol"},{"key":"4763_CR79","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/eye.2009.203","volume":"23","author":"N Dhingra","year":"2009","unstructured":"Dhingra N, Morgan J, Dick AD (2009) Switching biologic agents for uveitis. Eye 23:1868\u20131870","journal-title":"Eye"},{"key":"4763_CR80","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3109\/09273948.2013.844265","volume":"22","author":"E Miserocchi","year":"2014","unstructured":"Miserocchi E, Modorati G, Pontikaki I, Meroni PL, Gerloni V (2014) Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm 22:90\u201395","journal-title":"Ocul Immunol Inflamm"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04763-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-019-04763-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04763-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T21:02:09Z","timestamp":1695502929000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-019-04763-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,10]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["4763"],"URL":"https:\/\/doi.org\/10.1007\/s10067-019-04763-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,10]]},"assertion":[{"value":"22 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}